U.S. markets closed

PDL BioPharma, Inc. (PDLI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.5600+0.0600 (+2.40%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.5000
Open2.5000
Bid2.4700 x 1300
Ask2.5700 x 4000
Day's Range2.4650 - 2.5650
52 Week Range2.0900 - 3.8600
Volume1,602,084
Avg. Volume1,017,829
Market Cap292.421M
Beta (5Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-1.3240
Earnings DateNov 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 02, 2016
1y Target Est2.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • PDL Biopharma Inc (PDLI) Q3 2020 Earnings Call Transcript
    Motley Fool

    PDL Biopharma Inc (PDLI) Q3 2020 Earnings Call Transcript

    Please note that a slide presentation to accompany management's prepared remarks is available in the Investor Relations section of the PDL website at pdl.com. Joining me today from PDL BioPharma are Dominique Monnet, President and CEO; Edward Imbrogno, Vice President and CFO; and Chris Stone, Vice President and General Counsel. Please turn to Slide 2 and let me remind you that during this call management will be making forward-looking statements regarding the Company's financial performance and other matters and actual results may differ materially from those expressed in or implied by the forward-looking statements.

  • Benzinga

    Recap: PDL BioPharma Q3 Earnings

    Shares of PDL BioPharma (NASDAQ:PDLI) rose 7.96% in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share were down 211.11% year over year to ($0.10), which missed the estimate of $0.06.Revenue of $4,115,000 declined by 90.68% from the same period last year, which missed the estimate of $5,500,000.Guidance Earnings guidance hasn't been issued by the company for now.View more earnings on PDLIPDL BioPharma hasn't issued any revenue guidance for the time being.Technicals Company's 52-week high was at $3.86Company's 52-week low was at $2.09Price action over last quarter: down 17.60%Company Description PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.See more from Benzinga * Click here for options trades from Benzinga * Recap: TELA Bio Q3 Earnings * Recap: Beyond Air Q2 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • PDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of Dissolution
    PR Newswire

    PDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of Dissolution

    PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 2020 and provides an update on important milestones achieved in the execution of its monetization and liquidation plan.